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Long-Term Use of Nonsteroidal Anti-inflammatory
Drugs Decreases the Risk of Cutaneous Melanoma:
Results of a United States Case–Control Study
Clara Curiel-Lewandrowski1,2, Tamar Nijsten3, Maria L. Gomez1, Loes M. Hollestein4, Michael B. Atkins5
and Robert S. Stern1
Experimental and observational studies continue to demonstrate conflicting results regarding the role of several
commonly used drugs as melanoma chemopreventive agents. This case–control study was designed to assess
the associations between cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs
(NSAIDs) and statins in current users. A total of 400 CM and 600 eligible age- and gender-matched community-
based controls were prospectively recruited and interviewed. We assessed participants’ demographic
characteristics, CM risk factors, and current and previous use of medications. Multivariable conditional logistic
regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for
associations between NSAIDs and/or aspirin (ASA), statin exposure, and CM risk. Half of the subjects were men
(mean age 60 years). After adjusting for confounders, use of any type of NSAIDs for more than 5 years
significantly reduced the risk of melanoma development compared with the low-exposure group (adjusted
OR¼ 0.57; 95% CI¼ 0.43–0.77). Subgroup analyses showed that the observed risk reduction was primarily driven
by continuous ASA use (45 years adjusted OR¼ 0.51, 95% CI¼ 0.35–0.75). No significant protective effect was
observed with statin exposure (OR¼ 0.97, 95% CI¼ 0.73–1.29). Long-term use of NSAIDs, especially ASA, is
associated with a significantly decreased risk of CM development. Clinical intervention studies are warranted to
further investigate the potential role of ASA and other NSAIDs as chemopreventive agents for CM.
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INTRODUCTION
With the incidence and mortality of malignant cutaneous
melanoma (CM) increasing more rapidly than other common
cancers in the US (Jemal et al., 2009), prevention efforts,
beyond reduction in sun exposure, merit additional con-
sideration (Bordeaux et al., 2007; Tucker, 2009).
Chemoprevention is a relatively unexplored strategy to reduce
the incidence of CM (Vogel, 2007). Commonly used drugs such as
nonsteroidal anti-inflammatory drugs (NSAIDs), including acetyl-
salicylic acid (ASA), and statins with acceptable safety and other
potential health benefits are appealing candidates for chemopre-
vention. The protective effect of NSAIDs has been confirmed by
multiple studies for colorectal cancer (Gonza´lez-Pe´rez et al., 2003;
Dube` et al., 2007) with findings suggesting the need for extended
and frequent NSAID exposure, usually beyond 5 years (Gonza´lez-
Pe´rez et al., 2003). Less definitive data exist in the setting of breast,
esophagus, and stomach cancers (Zerbini et al., 2006).
Several in vitro and observational studies have suggested
that regular use of NSAIDs, and statins may reduce the
likelihood of CM development and progression, but not all
studies have been supportive of this association resulting in
overall conflicting results (Downs et al., 1998; Jeter et al.,
2005; Ramirez et al., 2005; Koomen et al., 2007; Asgari
et al., 2008; Kuoppala et al., 2008; Joosse et al., 2009;
Bonovas et al., 2010). Therefore, population-based epide-
miological studies specifically designed to evaluate the role
of these commonly prescribed drugs, as potential chemopre-
ventive agents for CM are needed.
The objective of this case–control study was to assess the
association of long-term use of lipid-lowering agents (LLAs)
and NSAIDs use with CM risk.
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RESULTS
Sample
About half the cases and controls were female with a mean
age of 58 years (Table 1). More than 96% of cases and
controls were Caucasian. No statistically significant differ-
ences in the distribution of marital status, education level,
working status, annual income, and smoking status were
observed between cases and community-matched controls.
The utilization of health care was comparable between cases
and controls, except that CM patients reported more skin
checks during their life before diagnosis than did controls
(X6; odds ratio (OR)¼1.48 (95% confidence interval (CI)
1.06–2.07) compared with no skin checks; Table 1).
Several phenotypic characteristics including light hair
and eye color, and increased number of moles and freckles
were associated with a 2- to 3-fold-increased risk of CM.
Skin response to sun, weeks at the beach, and number
of sunburns were significantly higher among cases than
Table 1. Distribution of selected demographics,
lifestyle factors, and health-care utilization between
cases and controls, and univariate logistic regression
analysis
Characteristic
No. of cases
(%) (n=400)
No. of controls
(%) (n=600)
Crude OR
(95% CI)
Age (years)
40–44 48 (12) 61 (10) 1.00 (Reference)
45–54 116 (29) 194 (32) 0.79 (0.52–1.21)
55–64 117 (29) 174 (29) 0.88 (0.58–1.36)
65–74 77 (19) 105 (18) 0.97 (0.61–1.54)
475 42 (11) 66 (11) 0.86 (0.49–1.48)
Gender
Female 193 (48) 301 (50) 1.00 (Reference)
Male 207 (52) 299 (50) 1.08 (0.84–1.34)
Ethnicity
Non-white 3 (1) 15 (3) 1.00 (Reference)
White 397 (99) 585 (97) 4.75 (1.41–16.03)
Marital status
Married 304 (76) 464 (77) 1.00 (Reference)
Single 39 (10) 51 (9) 1.17 (0.75–1.81)
Other 57 (15) 85 (14) 1.02 (0.71–1.47)
Education
High school
graduate or less
74 (19) 121 (20) 1.00 (Reference)
College graduate
or less
184 (46) 264 (44) 1.14 (0.81–1.61)
Graduate school 138 (35) 208 (35) 1.09 (0.76–1.56)
Working status
Full time 202 (51) 272 (45) NA
Retired 116 (30) 181 (30)
Other 82 (21) 147 (25)
Annual household income ($)
p30,000 36 (9) 55 (9) 1.00 (Reference)
430,000–75,000 112 (28) 178 (30) 0.96 (0.58–1.60)
475,000 208 (47) 246 (41) 1.30 (0.80–2.11)
Not provided 44 (11) 121 (20) 0.56 (0.31–0.99)
Time in present residence
410 years 239 (60) 434 (72) 1.00 (Reference)
6–10 years 79 (20) 106 (18) 1.35 (0.96–1.91)
o5 years 82 (21) 57 (10) 2.61 (1.77–3.86)
Table 1. Continued
Characteristic
No. of cases
(%) (n=400)
No. of controls
(%) (n=600)
Crude OR
(95% CI)
Smoking status
Never smoked 164 (41) 266 (44) 1.00 (Reference)
Former smoker 196 (49) 260 (43) 1.22 (0.93–1.61)
Current smokers 31 (8) 60 (10) 0.84 (0.51–1.38)
Visits to primary care physician per year
0–2 262 (66) 430 (72) 1.00 (Reference)
3–5 106 (27) 141 (24) 1.23 (0.92–1.66)
X6 31 (8) 29 (5) 1.75 (1.03–2.98)
Visits to a medical specialist per year
0 85 (21) 170 (28) 1.00 (Reference)
1–2 169 (42) 242 (40) 1.40 (1.01–1.94)
3–5 100 (25) 128 (21) 1.56 (1.08–2.26)
X6 46 (12) 60 (10) 1.53 (0.96–2.44)
Skin checks: times in lifetime
0 117 (29) 191 (32) 1.00 (Reference)
1–2 100 (25) 188 (31) 0.87 (0.62–1.21)
3–5 56 (14) 81 (14) 1.23 (0.75–1.70)
X6 125 (31) 138 (23) 1.48 (1.06–2.07)
Number of prescription medications used in the last year
None 123 (31) 196 (33) 1.00 (Reference)
1–2 132 (33) 214 (36) 0.98 (0.72–1.34)
3–5 109 (27) 146 (24) 1.19 (0.85–1.66)
X6 36 (9) 42 (7) 1.37 (0.83–2.25)
Abbreviation: NA, not applicable.
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controls (Table 2). Most cases had a superficial spreading
histological subtype of melanoma (46%) and almost half
(48%) had a Breslow thickness o1 mm, and a quarter were
thicker than 2 mm.
Statins and CM
Of the 280 users of LLAs, 276 (98.6%) reported taking statins
in the last 12 months. All of those users reported a frequency
of exposure 44 days per week. Participants reported using
atorvastatin (69.9%), simvastatin (17.8%), pravastatin (5.1%),
rosuvastatin (2.9%), lovastatin (2.1%), and fluvastatin (2.1%).
Cases and controls had similar use of statins (27.3 vs. 27.8%;
OR¼0.97, 95% CI¼ 0.73–1.29; Table 3). The proportion of
Table 2. Distribution of possible melanoma risk
factors between melanoma cases and controls
Possible risk
factor
No. of cases
(n=400)(%)
No. of controls
(n=600) No. (%)
OR
(95% CI)
Hair color
Dark brown to
black
76 (19) 177 (30) 1.00 (Reference)
Medium brown 124 (31) 187 (31) 1.54 (1.09–2.20)
Blond to
light brown
164 (41) 210 (35) 1.82 (1.30–2.55)
Red 36 (9) 26 (4) 3.23 (1.82–5.71)
Eye color
Brown 108 (27) 211 (35) 1.00 (Reference)
Green or hazel 135 (34) 169 (28) 1.56 (1.13–2.16)
Blue or gray 157 (39) 220 (37) 1.39 (1.023–1.90)
Previous Hx of NMSC
No 326 (82) 523 (87) 1.00 (Reference)
Yes 74 (19) 76 (13) 1.56 (1.10–2.21)
Family Hx of melanoma
No 335 (84) 511 (85) 1.00 (Reference)
Yes 59 (15) 64 (11) 1.41 (0.96–2.06)
Number of moles as a teenager
I had no moles 83 (21) 193 (32) 1.00 (Reference)
I had a few moles 271 (68) 372 (62) 1.69 (1.25–2.29)
I had many moles 44 (11) 30 (5) 3.41 (2.01–5.80)
Number of freckles
Face/teen
I had no
freckles
125 (31) 290 (48) 1.00 (Reference)
I had a few
freckles
194 (49) 221 (37) 2.04 (1.53–2.71)
I had many
freckles
81 (20) 84 (14) 2.24 (1.55–3.24)
Arms/teen
I had no
freckles
87 (22) 245 (41) 1.00 (Reference)
I had a few
freckles
222 (56) 264 (44) 2.37 (1.75–3.21)
I had many
freckles
91 (23) 87 (15) 2.95 (2.01–4.32)
Skin response to strong sunlight
At the beginning of summer
No burn 37 (9) 102 (17) 1.00 (Reference)
Mild burn 225 (56) 346 (58) 1.79 (1.19–2.71)
Severe or painful
burn
135 (34) 150 (25) 2.48 (1.59–3.86)
Table 2. Continued
Possible risk
factor
No. of cases
(n=400)(%)
No. of controls
(n=600) No. (%)
OR
(95% CI)
Skin response at the end of summer
Deep tan 64 (16) 162 (27) 1.00 (Reference)
Mild or moderate
tan
290 (73) 384 (64) 1.91 (1.38–2.65)
No tan 38 (10) 50 (8) 1.92 (1.15–3.21)
No. of weeks/year at the beach
As an adolescent
0 66 (17) 141 (24) 1.00 (Reference)
1 74 (19) 119 (20) 1.33 (0.88–2.01)
2–3 112 (28) 142 (24) 1.69 (1.15–2.47)
X4 146 (37) 198 (33) 1.58 (1.10–2.26)
In the past 5 years
0 124 (31) 219 (37) 1.00 (Reference)
1 91 (23) 125 (21) 1.29 (0.91–1.82)
2–3 104 (26) 130 (22) 1.41 (1.01–1.98)
X4 80 (20) 126 (21) 1.12 (0.79–1.60)
Number of sunburns
As a child
0 136 (34) 294 (49) 1.00 (Reference)
1–4 131 (33) 175 (29) 1.61 (1.19–2.19)
44 108 (27) 100 (17) 2.34 (1.66–3.28)
As an adolescent
0 133 (33) 252 (42) 1.00 (Reference)
1 140 (35) 194 (32) 1.37 (1.01–1.85)
X2 127 (32) 154 (26) 1.56 (1.14–2.14)
Sun bed use
(times/lifetime)
0 311 (78) 482 (80) 1.00 (Reference)
o10 37 (9) 61 (10) 0.94 (0.60–1.48)
X10 52 (13) 57 (10) 1.41 (0.93–2.15)
Abbreviations: CI, confidence interval; Hx, history; NMSC, non-melano-
ma skin cancer; OR, odds ratio.
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cases and controls that had used statins for 45 years was
comparable (5.0 and 6.0%, respectively) and prolonged
exposure to statins was not associated with a decreased risk
of CM (OR¼ 0.84, 95% CI¼0.48–1.48 compared with o2
years; Table 3). Men demonstrated a higher prevalence of
statin use than women (36 vs. 19%), but the findings were
comparable after stratification for gender (Table 4).
NSAIDs and melanoma
Of the 1,000 cases and controls, 695 (69.5%) reported
exposure to NSAIDs within the year before the interview. Of
these 695 participants, 402 (57.8%) had used ASA (Table 3).
Among the non-ASA NSAID users, the most commonly used
drugs were ibuprofen (45.3%) and naproxen (10.6%). Only
6.6% of participants reported exposure to Cox-2 inhibitors.
Table 3. Comparison of statin and NSAID exposure measures between melanoma cases and controls
Drug exposure No. of cases (n=400) (%) No. of controls (n=600) (%) (Adjusted) OR (95% CI) Multivariate OR (95% CI)
Statin use
No use 291 (73) 433 (72) 1.00 (Reference) NA
Any use 109 (27) 167 (28) 0.97 (0.73–1.29)
Duration of any statin use (years)1
o2 or no use 317 (79) 479 (80) 1.00 (Reference) NA
2–5 63 (16) 85 (14) 1.12 (0.79–1.60)
45 20 (5) 36 (6) 0.84 (0.48–1.48)
Any NSAID use1
No use 138 (35) 167 (28) 1.00 (Reference) NA
Any use 262 (66) 433 (72) 0.73 (0.56–0.96)
Duration of any NSAID use (years)1
o2 or no use 179 (45) 226 (38) 1.00 (Reference) NA
2–5 110 (28) 129 (22) 1.08 (0.78–1.48)
45 111 (28) 245 (41) 0.57 (0.43–0.77)
Any ASA use (±NSAID)2
No use 256 (64) 342 (57) NA 1.00 (Reference)
Any use 144 (36) 258 (43) 0.72 (0.55–0.94)
Duration of use of ASA (years)2
o2 or no use 279 (70) 381 (64) NA 1.00 (Reference)
2–5 68 (17) 92 (15) 1.03 (0.72–1.49)
45 53 (13) 127 (21) 0.51 (0.35–0.75)
Any use of a non-ASA NSAID (±ASA)3
No use 237 (59) 349 (58) NA 1.00 (Reference)
Any use 163 (41) 251 (42) 0.92 (0.70–1.19)
Duration of use of a non-ASA NSAID (years)3
o2 or no use 268 (67) 382 (64) NA 1.00 (Reference)
2–5 60 (15) 73 (12) 1.25 (0.85–1.83)
45 72 (18) 145 (24) 0.64 (0.46–0.89)
Abbreviations: ASA, acetyl salicylic acid; CI, confidence interval; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.
1Not adjusted in multivariate model, except age-, gender-, and town-matched.
2Adjusted for number of sunburns during childhood.
3Adjusted for extent of freckling on arms.
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Table 4. Comparison of statin and NSAID exposure measures between melanoma cases and controls stratified for
gender
Males Females
Drug
exposure
No. of cases
(n=207) (%)
No. of controls
(n=299) (%)
(Adjusted) OR
(95% CI)
Multivariate OR
(95% CI)
No. of cases
(n=193) (%)
No. of controls
(n=301) (%)
(Adjusted)
OR (95% CI)
Multivariate
OR (95% CI)
Statin use
No use 134 (65) 191 (64) 1.00 (Reference) NA 157 (81) 242 (80) 1.00 (Reference) NA
Any use 73 (35) 108 (36) 0.96 (0.67–1.40) 36 (19) 59 (20) 0.94 (0.59–1.49)
Duration of any statin use (years)1
o2 or no
use
149 (72) 219 (73) 1.00 (Reference) NA 168 (87) 260 (86) 1.00 (Reference) NA
2–5 43 (21) 51 (17) 1.24 (0.79–1.96) 20 (10) 34 (11) 0.91 (0.51–1.64)
45 15 (7) 29 (10) 0.76 (0.39–1.47) 5 (3) 7 (2) 1.11 (0.35–3.54)
Any NSAID use1
No use 69 (33) 89 (30) 1.00 (Reference) NA 69 (36) 78 (26) 1.00 (Reference) NA
Any use 138 (67) 210 (70) 0.85 (0.58–1.24) 124 (64) 223 (74) 0.63 (0.43–0.93)
Duration of any NSAID use (years)1
o2 or no
use
90 (44) 116 (39) 1.00 (Reference) NA 89 (46) 110 (37) 1.00 (Reference) NA
2–5 65 (31) 70 (23) 1.20 (0.77–1.85) 45 (23) 59 (20) 0.94 (0.58–1.52)
45 52 (25) 113 (38) 0.59 (0.39–0.91) 59 (31) 132 (44) 0.55 (0.37–0.84)
Any ASA use (±NSAID)2
No use 115 (56) 146 (49) NA 1.00 (Reference) 141 (73) 196 (65) NA 1.00 (Reference)
Any use 92 (44) 153 (51) 0.73 (0.50–1.08) 52 (27) 105 (35) 0.67 (0.45–1.02)
Duration of use of ASA (years)2
o2 or no
use
127 (61) 169 (57) NA 1.00 (Reference) 152 (79) 212 (71) NA 1.00 (Reference)
2–5 46 (22) 56 (19) 1.03 (0.66–1.71) 22 (11) 36 (12) 0.98 (0.55–1.77)
45 34 (16) 74 (25) 0.56 (0.34–0.92) 19 (10) 53 (18) 0.44 (0.24–0.81)
Any use of a non-ASA NSAID (±ASA)3
No use 138 (67) 199 (67) NA 1.00 (Reference) 99 (51) 150 (50) NA 1.00 (Reference)
Any use 69 (33) 100 (33) 0.95 (0.65–1.40) 94 (49) 151 (50) 0.92 (0.64–1.34)
Duration of use of a non-ASA NSAID (years)3
o2 or non-
exposed
154 (74) 209 (70) NA 1.00 (Reference) 114 (59) 173 (58) NA 1.00 (Reference)
2–5 28 (14) 38 (13) 1.03 (0.60–1.78) 32 (17) 35 (12) 1.53 (0.88–2.65)
45 25 (12) 52 (17) 0.61 (0.36–1.04) 47 (24) 93 (31) 0.69 (0.45–1.08)
Abbreviations: ASA, acetyl salicylic acid; CI, confidence interval; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.
1Not adjusted in multivariate model, except age-, gender-, and town-matched.
2Adjusted for number of sunburns during childhood.
3Adjusted for extent of freckling on arms.
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Overall, controls were more likely than cases to have used
NSAIDs 4–5 times weekly (4.2 vs. 1.8%).
The distribution of several NSAID exposure measures
among CM cases and controls are presented in Table 3. Age-
and gender-matched controls were significantly more likely to
have longer NSAID exposure (Tables 3 and 4). After adjusting
for potential confounders in a multivariate model, the use of at
least one NSAID for 45 years decreased the likelihood of
developing CM by almost half (adjusted OR¼0.57; 95%
CI¼0.43–0.77 compared with o2 years and no-use).
Comparing with cases, a significantly higher proportion of
controls reported ASA use in the past year (overall exposure:
43 vs. 36%). After adjusting for sunburns during childhood
(see Tables 3 and 4 for adjusted variables), people who used
ASA were still about 25% less likely to have a CM diagnosis
(adjusted OR¼0.72; 95% CI¼0.55–0.94). Controls were
also more likely to have used ASA for 45 years than cases
(21 vs. 13%, P¼ 0.002). For long-term ASA users, CM risk
was about half that of never-users of ASA or of those who had
used ASA for o2 years, after adjusting for sunburns during
childhood (adjusted OR¼0.51; 95% CI¼0.35–0.75)
The use of non-ASA NSAIDs (with or without prior and/or
concomitant exposure to ASA) did not differ between
cases and controls (41 vs. 42%, adjusted OR¼ 0.92; 95%
CI¼0.70–1.19). However, controls were slightly more likely
than cases to have used non-ASA NSAIDs for 45 years (24
vs.18%, P¼ 0.072). Participants who used non-ASA NSAID
for 45 years were significantly less likely to develop CM
compared with participants who used it for 2 years or less
(adjusted OR¼0.64; 95% CI¼0.46–0.89).
Sensitivity analyses
Restricting the univariate analyses to participants who used
ASA without previous and/or concomitant exposure to
other NSAIDs did not change the findings substantially
(45 years: OR¼0.48; 95% CI¼0.31–0.74 compared with
o2 years-of-use). Also, the NSAID analysis that excluded
participants who used ASA was comparable to the presented
results (45 years: OR¼ 0.63; 95% CI¼0.43–0.93 compared
with o2 years-of-use).
Including all variables that were significantly associated with
CM in the univariate analysis into a full multivariate model
showed similar findings for long-term use of all NSAIDs (45
years; adjusted OR¼0.57, 95% CI¼0.42–0.77, compared with
o2 years-of-use), and ASA use (45 years; adjusted OR¼ 0.50,
95% CI¼0.30–0.82, compared with o2 years-of-use). In
contrast to the multivariate analysis that included variables
based on the bivariate approach, non-ASA NSAID use (±ASA
exposure) for 45 years was associated with a significantly
reduced melanoma risk (45 years; adjusted OR¼ 0.64, 95%
CI¼0.46–0.89, compared with o2 years-of-use).
In the multivariate model that included variables based on
the level of significance in the univariate analysis, partici-
pants who used non-ASA NSAID without concomitant ASA
exposure remained significantly less likely to develop CM
(45 years; adjusted OR¼0.61; 95% CI¼0.40–0.93 com-
pared with o2 years-of-use). After stratification for gender,
the protective effect of NSAID and ASA exposure for 45
years was similar to those of the entire study population, with
a trend toward a more pronounced effect in women (Table 4).
DISCUSSION
NSAIDs and melanoma
The findings of this case–control study indicate that continuous
use of ASA for 5 years or more reduces the CM risk by almost
half. This suggests the need of longer exposure for potential
chemopreventive agents such as ASA to exert a protective
biological effect (Elwood et al., 2009). Regular, long-term use
of non-ASA NSAIDs may also reduce CM risk, but because
only 25% of non-ASA NSAID users were taking the medica-
tions X4 times weekly the power to detect a significant
association is limited. In contrast to a recent Dutch pharmaco-
epidemiological study, we observed a protective effect of ASA
on CM development in both men and women (Joosse et al.,
2009). In addition to a different dosing regimen, ASA may have
a different effect on CM development than other NSAIDs
because of its anti-oxidant properties, inhibition of activation of
NF-kb, upregulation of tumor suppressor genes such as TP53,
CDKN1A, and BAX, and the downregulation of anti-apoptotic
genes such as BCL2 (Elwood et al., 2009).
It is difficult to compare our findings with other studies
because of the difference in study design and exposure
definition. Two cohort studies have demonstrated a potential
protective effect by NSAIDs in women exposed to continues
use of low-dose ASA and in the setting of Cox-2 inhibitor
exposure when assessing for incidence of second primaries,
metastatic disease, and recurrences (Ramirez et al., 2005;
Joosse et al., 2009). The Vitamins and Lifestyle cohort
study did not detect a protective effect of NSAIDs on CM
development, but this study had the following limitations:
(1) NSAID exposure was defined as at least once weekly
NSAID use for 1 year in the last 10 years without other
temporal association other than ‘‘preceding’’ the date of
diagnosis of melanoma; and (2) the magnitude of effect for
several known melanoma risk factors, such as family history,
hair color, and skin reaction to sunlight, were not confirmed
in this study (Asgari et al., 2008).
Statins and melanoma
Our initial statistical consideration assumed a 20% prevalence
of statin use. We observed an overall 28% exposure rate, which
could be explained by the increasing rate of statin use observed
in the last decade. The prevalence of statin use in our
case–control study, including gender distribution, is in range
with recently reported studies (Ma et al., 2005; Buettner et al.,
2008). A similar rate of statin exposure was observed between
cases and controls irrespective of potential relevant factors such
as duration of use and gender effect (Tables 3 and 4). In
addition, all users related a frequency of exposure 44 times
per week further supporting the negative association between
statin exposure and melanoma risk reduction.
This neutral effect of statins in melanoma incidence
concurs with two recent meta-analyses studies demonstrating
ORs ranging from 0.87 to 0.92 (Freeman et al., 2006;
Bonovas et al., 2010). In addition, studies evaluating the
chemopreventive effect of statins in multiple neoplasias have
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failed to demonstrate a reduction in short-term cancer risk
(Browning and Martin, 2007). Of interest, a positive effect of
statins in melanoma progression has been suggested by one
recent study (Koomen et al., 2007). The authors identified
that statin use was associated with a reduced Breslow
thickness (19%, 95% CI¼33, 2.3, P¼0.03) without
significant impact on overall melanoma incidence.
Strengths and limitations
This large case–control study was specifically designed to test
the associations between drug exposure and CM development.
In total, 400 melanoma patients participated, but a limited
sample size (i.e., type II error) may have affected our findings,
especially for the chemopreventive effects of non-ASA NSAIDs.
As the initial sample size calculations were based on the
association between statin exposure and CM risk, the statistical
power was calculated post hoc for all NSAIDS and ASA based
on the proportions of cases and controls who were exposed to
these drugs for 45 years (28 vs. 41% and 13 vs. 21%,
respectively) and was high at an alpha level of 0.05 (99.6 and
90.9%, respectively). The controls were population based and
matched for age, gender, and community. Although it could be
argued that this approach introduced overmatching, which
would tend to underestimate associations, this procedure was
chosen to minimize biases due to differences in sociodemo-
graphic factors, health care access, ethnicity, and possibly
several lifestyle exposures (Le Marchand et al., 2006; Whiteman
et al., 2006). Our confirmation of known melanoma risk factors
such as demographics, phenotype, sun exposure, and lifestyle
supports the accuracy of our data (Le Marchand et al., 2006;
Whiteman et al., 2006; Tucker, 2009).
In the Materials and Methods section, we indicate that the
selection of participants 440 years of age was based on
general population exposure to statins. Several case–control
studies evaluating the relationship of statins and NSAID
exposure on cancer incidence have used a similar age cutoff
(Shadman et al., 2009; Yu et al., 2009). This approach raises
the possibility of selection bias; however, SEER data suggest
that the probability of developing melanoma within birth to
age 39 by gender between 2002 and 2005 was significantly
lower when compared with those 440 years of age (Jemal
et al., 2009); therefore our results are likely relevant to the
majority of the population at risk for melanoma. An inherent
potential limitation in the recruitment of community controls
relates to the risk of selection bias toward individuals with
greater awareness toward health-related inquiries; however,
cases and controls responded similarly to the indication of use
for ASA (71 vs. 73% respectively), and both groups demon-
strating similar level of access to medical care (Table 1).
The specific focus of the overall study was exposure to
medications and we sought to limit recall bias. We used
structured questions to elicit information on NSAID and statin
exposure and read a list of all generic and brand names of the
most commonly used drugs to participants. The doses of drugs
used and their precise indication were not assessed because of
their complexity (especially for NSAIDs). Although we did not
verify the data from the standardized retrospective drug history
by any other means (e.g., contacting primary care physicians,
pharmacy, or hospital records), types of NSAIDs and statins used
were similar between cases and controls and the most frequently
used NSAID (70% was accounted for by ASA and ibuprofen) and
statins (70% accounted for atorvastatin) was in accordance with
previously reported data. (Ma et al., 2005). This suggests that
recall bias was low and most likely to be non-differential, which
would then bias the risk estimates toward the null hypothesis.
Typically non-ASA NSAIDs are commonly used short-term
for acute inflammatory processes and ASA more often long-
term for cardiovascular disease prophylaxis (e.g., daily low-
dose ASA). Although the specific ASA dose was not
ascertained, 70% of people who indicated exposure to ASA
used it X4 times a week suggesting possible use for
cardiovascular prophylaxis. In contrast to previous studies,
we were able to evaluate the temporal association of long-
term NSAID and melanoma detection in more detail.
Future melanoma chemoprevention strategies will likely be
subjected to the current notion that multiple pathways of
melanoma pathogenesis exist. This theory asserts that certain
types of melanoma (i.e., head and neck) may be more prevalent
in individuals with higher cumulative doses of sun exposure and
low nevus counts, whereas intermittent UV exposure may be
more closely linked to truncal melanoma and high nevus counts
(Whiteman et al., 2003). Also recent data have shown that
differences in frequency of BRAF or NRAS mutations are also
related to patterns of sun exposure (Curtin et al., 2005).
In summary, our findings suggest that long-term use of
NSAIDs, particularly ASA, decreases the risk of CM by half, with
statin exposure demonstrating a neutral effect. The chemopre-
ventive property of ASA in cancer development may be an
additional argument to strongly encourage ASA adherence
(Elwood et al., 2009). Considering the risk to benefit ratio of
low-dose ASA including the risk for bleeding and its cardiovas-
cular effects, ASA would be an ideal candidate for clinical
chemoprevention studies in melanoma in very high-risk
populations (e.g., familial melanoma syndrome, atypical mole
syndrome, and previous melanoma) or in populations using
ASA for other health endpoints. In addition, the potential effect
of NSAIDs in melanoma progression should be further explored.
MATERIALS AND METHODS
Sample
CM cases were recruited from the melanoma clinics and dermatology
practices at affiliated Dana Farber Harvard Cancer Center institutions
and Dermatology Associates of Concord, Boston (USA) from 15 March
2004 to 18 June 2007 (Figure 1). The Dana Farber Harvard Cancer
Center and the New England Institutional Review Board approved the
study and all procedures. Written informed patient consent was
waived to minimize ascertainment bias between cases and controls. A
verbal consent was obtained for all participating subjects and the
protocol was compliant with the Helsinki Guidelines. Cases were
eligible if they were at least 40 years of age, spoke English, were able
to complete a telephone interview, and had received a diagnosis of
primary CM within 90 days from the recruitment date. The rationale
for recruiting individuals at least 40 years of age was based on the low
prevalence of drug exposure, particularly for statins, in younger cohorts
(see statistical analysis section). We contacted cases after their
physician had obtained verbal consent. Of 483 cases that were invited
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to participate 449 verbally consented, and a total of 400 completed the
interview (Figure 1). After completing the interview with a case, we
matched each case to seven potential controls of the same sex, 5-year
age-group, and home precinct obtained from city/town registry of adult
residents (Sakamoto et al., 2006; Zhang et al., 2009). To minimize
variability in the interview process (see data collection section), we
approached cases and controls similarly by mailing an invitation letter
explaining the telephone interview process without revealing our key
study objective. All participants were asked to list current and former
exposure to prescription and over the counter medications targeted in
the study. Of the 2,800 potential-matched controls who were sent an
invitation letter, we successfully contacted 1,805 after one to three
telephone calls, 999 declined participation and 206 were not eligible.
Every case had at least one interviewed age- and gender-matched
control, and half of the CM cases were successfully matched with
two controls (on average a 1:1.5 ratio), ultimately resulting in 608
consented and interviewed age- and gender-matched controls,
representing 21.4% out of 57.1% of contacted and eligible controls
(Figure 1). Of these, eight with a history of melanoma were excluded.
Data collection
Four trained interviewers telephoned all participants, verbally
consented the controls, and administered a 42-item questionnaire
that elicited information on demographic characteristics, medical
history, and lifestyle characteristics, including utilization of medical
care, known CM risk factors, and medication use (Rosso et al.,
1996, 2002; Zanetti et al., 1996). (See Tables 1 and 2 for selected
variables). The questionnaire took an average of 25 minutes to
complete and participants were not compensated for their time. Data
entry was checked for consistency of data entry by re-entering 50
interviews into a separate database. This procedure detected errors
in only 0.5% of entries.
Assessment of medication use
We defined current NSAID, ASA, LLA, and statin users as persons
taking the drug at least once weekly within a year preceding the
interview. The interviewers ascertained drug exposure history in three
ways by asking participants to (1) list the number of current
prescription and over the counter medications taken at least once
weekly in the last year; (2) identify medical conditions that might be
associated with use of the drug classes of interest (for NSAIDs, any use
within the last year of a prescription or over the counter drug for pain,
headache, arthritis, cardiovascular prophylaxis, or for other typical
indications. For LLAs, any history of hyperlipidemia and treatment); (3)
verify names of drugs in response to the interviewer’s listing of the most
commonly used NSAIDs (that reflected more than 90% of NSAIDs
marketed in the US), and a complete listing of LLAs (including fibrates
and statins) using generic and brand names (Intercontinental Marketing
Services website: http://www.imshealth.com/portal/site/imshealth, ac-
cessed 27 January 2004). The interviewer recorded the drug name,
frequency, and duration of use given by the respondent.
For NSAIDs and LLAs users, we assessed the drug with longest
exposure duration. Among individual NSAIDs, the pattern of use
could vary considerably, so we also assessed the following NSAIDs
exposures: (1) all NSAIDs (ASA and non-ASA NSAIDs); (2) ASA with
or without concomitant NSAIDs exposure, and (3) non-ASA NSAIDs
with or without ASA exposure.
Statistical analysis
The analyses of the data reported on this paper were on the study
hypotheses that focused on the association between NSAID and
statin use and CM development. Sample size calculations were
based on the prevalence of drug use and risk reduction assumption.
In the case of statins, which have lower prevalence or use, it was
assumed that 20% of the general population age 45 years and older
used statins (personal communication by Dr D. Kaufman) and that
the expected CM risk reduction would be 30%, as suggested in other
studies of chemopreventive agents. With an a¼ 0.05, b¼ 0.80, and a
1:2 ratio for cases and controls, about 500 cases and 1,000 controls
needed to be enrolled. However, following interim analysis the
studied was halted at 400 cases when no association between statins
and CM risk reduction was observed.
Continuous variables were presented as means, and standard
deviations. Mean differences between cases and controls were
assessed with the Student’s t-test. Differences between groups in the
distribution of categorical variables were tested using the w2 test. We
used univariate conditional logistic regression models to analyze the
association between NSAIDs, ASA, statins, and CM by calculating
ORs with 95% CI. Potential confounding factors were evaluated
based on whether inclusion of the factor into the regression model
changed the OR of NSAID, ASA, and CM risk by 10% or more
(‘‘bivariate approach’’; Vandenbroucke et al., 2007). Modeling was
conducted for statins, and each of the three definitions of NSAIDs.
We categorized duration of exposure for NSAID, ASA, or statins into
Dermatology and melanoma specialty
clinics in Boston (MA), USA (′04–′07)
2,800 Age- and gender-
matched controls invited by mail
1,805 Controls contacted
600 Controls
interviewed by telephone
-Not available (995)
-Not reachable (564)
-No contact (431)
-Declined (999)
-Not eligible (206)
-History of melanoma (8)
449 Melanoma cases
-BIDMC (202)
-MGH (118)
-BWH/DFCI (74)
-Concord (6)
- 11 Ineligible
- 38 Refused
400 Cases interviewed by
telephone
(>45 years old) consented:
Figure 1. Ascertainment of Cases and Controls. BIDMC, Beth Israel Deaconess Medical Center; MGH, Massachusetts General Hospital; BWH/DFCI, Brigham
and Women’s Hospital/Dana Farber Cancer Institute.
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o2 years, 2–5 years, and 45 years (Dube` et al., 2007). In our final
analysis, we combined the ‘‘never exposed’’ and ‘‘exposed for less
than 2 years’’ categories because exposure ofo2 years before index
date of CM is likely to have had no effect on CM carcinogenesis and
in preliminary analyses, and no significant differences in risk
estimates were identified between no-use ando2 years-of-exposure
for both study drugs (Dube` et al., 2007).
In sensitivity analyses, ASA exposure without previous or
concomitant NSAID use, and NSAID exposure without ASA use
were analyzed as dependent outcomes to assess possible differences
between the effects of these two drug classes. In addition to the
bivariate approach, we performed a multivariate analysis including
all variables that differed significantly between cases and controls in
the univariate analyses to test the impact of selecting confounders
using the bivariate approach.
All tests of statistical significance were two-sided and P-values
o0.05 were significant. Analyses were performed using STATA
statistical software, version 10 (College Station, TX) and SPSS
statistical software, version 17.0 (SPSS , Chicago, IL).
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